No Data
No Data
No Data
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
Jiangzhong Pharmaceutical (600750.SH) reported first-quarter results with net profit of 267 million yuan, up 9.99% year on year
According to the Zhitong Finance App, Jiangzhong Pharmaceutical (600750.SH) released its report for the first quarter of 2024, achieving revenue of 1,227 billion yuan, a year-on-year decrease of 8.74%. Net profit attributable to shareholders of listed companies was 267 million yuan, an increase of 9.99% over the previous year. Achieved net profit of 264 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 16.64% over the previous year.
Jiangzhong Pharmaceutical (600750): Gastrointestinal category leader's “high dividend+state-owned enterprise” value reshaping
Recommended logic: 1) Build a moat for gastrointestinal categories. It is estimated that in 2024, the scale of the pharmaceutical industry for gastrointestinal diseases in China is expected to reach 63.32 billion yuan, and the penetration rate of the core product, digestive tablets, will further increase. 2) Implementation of equity incentives. Achievements
Jiangzhong Pharmaceutical (600750): Improving Quality and Efficiency, High Growth, Brand Building Results Remarkable
Incident The company released an annual report. In 2023, it achieved revenue of 4.39 billion yuan, +13.00% year on year; realized net profit of 708 million yuan, +18.40% year-on-year, after deducting net profit of 704 million yuan.
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit in 2023 increased by 708 million yuan year on year, up 18.4% year on year
Gelonghui, March 25, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. Jiangzhong Pharmaceutical (600750.SH) announced its 2023 annual report, with operating revenue of RMB 4.39 billion, up 13.00% year on year; net profit attributable to Jiangzhong Pharmaceutical shareholders of RMB 708 million, up 18.4% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical (after deducting non-recurring income or loss) of 704 million yuan, an increase of 38.97% year on year; basic earnings per share were 1.12 yuan. A cash dividend of 7 yuan is distributed for every 10 shares.
Jiangzhong Pharmaceutical (600750): Performance is in line with expectations, high dividends, high quality assets
Event: On March 22, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 4.390 billion yuan, an increase of 13.00% over the previous year, and achieved net profit of 708 million yuan to mother
No Data